Climb Bio, Inc. (CLYM) vs Ginkgo Bioworks Holdings, Inc. (DNA)
Climb Bio, Inc. and Ginkgo Bioworks Holdings, Inc. are both Biotechnology companies. Climb Bio, Inc. and Ginkgo Bioworks Holdings, Inc. are of similar size ($683.6M and $682.9M). Climb Bio, Inc. has the higher net margin (0.00% vs −219.6%) and the higher return on invested capital (−71.7% vs −161.9%). Across the 12 metrics below, Climb Bio, Inc. leads on 9 and Ginkgo Bioworks Holdings, Inc. on 3.
Valuation
Profitability
| Metric | CLYM | DNA | Biotechnology median |
|---|---|---|---|
| Gross margin | — | 68.04% | 65.16% |
| Operating margin | 0.00% | (231.13%) | 0.00% |
| Net margin | 0.00% | (219.60%) | 0.00% |
| Free cash flow margin | 0.00% | (131.57%) | 0.00% |
| Return on equity | (27.10%) | (56.29%) | (57.72%) |
| Return on assets | (26.27%) | (26.19%) | (49.22%) |
| Return on invested capital | (71.73%) | (161.94%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack